50 96

Cited 3 times in

Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation

Authors
 Ho Sup Lee  ;  Yang Soo Kim  ;  Kihyun Kim  ;  Jin Seok Kim  ;  Hyo Jung Kim  ;  Chang-Ki Min  ;  Cheolwon Suh  ;  Hyeon-Seok Eom  ;  Sung-Soo Yoon  ;  Jae Hoon Lee  ;  Min Kyong Kim  ;  Sung-Hyun Kim  ;  Sung Hwa Bae  ;  Yeung-Chul Mun  ;  Deog Yeon Jo  ;  Joo-Seop Chung 
Citation
 JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.28(1) : 80-86, 2013 
Journal Title
 JOURNAL OF KOREAN MEDICAL SCIENCE 
ISSN
 1011-8934 
Issue Date
2013
MeSH
Aged ; Antineoplastic Agents/therapeutic use* ; Boronic Acids/therapeutic use* ; Bortezomib ; Disease-Free Survival ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy* ; Multiple Myeloma/mortality ; Predictive Value of Tests ; Pyrazines/therapeutic use* ; Registries ; Retrospective Studies ; Stem Cell Transplantation* ; Treatment Outcome
Keywords
Bortezomib ; Early Response ; Multiple Myeloma ; Survival
Abstract
Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival. The purpose of our study was to show how of early response to bortezomib combined chemotherapy influences survival in patients with newly diagnosed MM who are ineligible for stem cell transplantation. We assessed patient responses to at least four cycles of bortezomib using the International Myeloma Working Group response criteria. The endpoints were comparisons of progression free survival (PFS) and overall survival (OS) between early good response group (A group) and poor response group (B group). We retrospectively analyzed data from 129 patients registered by the Korean Multiple Myeloma Working Party, a nationwide registration of MM patients. The 3 yr PFS for the A and B groups was 55.6% and 18.4%, respectively (P < 0.001). The 3 yr OS for the A and B groups was 65.3% and 52.9%, respectively (P = 0.078). The early response to at least four cycle of bortezomib before next chemotherapy may help predict PFS in patients with MM who are ineligible stem cell transplantation
Files in This Item:
T999901260.pdf Download
DOI
10.3346/jkms.2013.28.1.80
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/165802
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse